{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:51:14Z","timestamp":1790405474971,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s40261-019-00771-y","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T03:29:36Z","timestamp":1552447776000},"page":"463-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Chronic Use of \u03b2-Blockers and the Risk of Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-0875","authenticated-orcid":false,"given":"Gideon","family":"Koren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Radinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varda","family":"Shalev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,13]]},"reference":[{"issue":"2","key":"771_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ana.10846","volume":"55","author":"M Farrer","year":"2004","unstructured":"Farrer M, Kachergus J, Forno L, et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol. 2004;55(2):174\u20139.","journal-title":"Ann Neurol"},{"issue":"11","key":"771_CR2","first-page":"10","volume":"25","author":"SL Wong","year":"2014","unstructured":"Wong SL, Gilmour H, Ramage-Morin PL. Parkinson\u2019s disease: prevalence, diagnosis and impact. Health Rep. 2014;25(11):10\u20134.","journal-title":"Health Rep"},{"issue":"11 Suppl 5","key":"771_CR3","first-page":"S21","volume":"54","author":"MC Rijk de","year":"2000","unstructured":"de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson\u2019s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(11 Suppl 5):S21\u20133.","journal-title":"Neurology"},{"issue":"6354","key":"771_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal S, Bj\u00f8rnevik K, Doo Soon I, et al. Beta 2-adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinsons disease. Science. 2017;357(6354):891\u20138.","journal-title":"Science."},{"key":"771_CR5","first-page":"CD002003","volume":"1","author":"CS Wiysonge","year":"2017","unstructured":"Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003.","journal-title":"Cochrane Database Syst Rev."},{"key":"771_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/mds.108","volume":"33","author":"N Gronich","year":"2018","unstructured":"Gronich N, Abernathy DR, Auriel E, et al. Beta 2 adrenoceptor agonists and antagonists and the risk of Parkinson\u2019s disease. Mov Disord. 2018;33:1465\u201371.","journal-title":"Mov Disord"},{"key":"771_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.25341","volume":"84","author":"S Searles-Nielsen","year":"2018","unstructured":"Searles-Nielsen S, Gross A, Camacho-Soto A, et al. Beta 2 adrenoreceptor medications and risk of Parkinson disease. Ann Neurol. 2018;84:683\u201393.","journal-title":"Ann Neurol"},{"key":"771_CR8","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1097\/IJG.0000000000000380","volume":"25","author":"I Goldshtein","year":"2016","unstructured":"Goldshtein I, Shalev V, Zigman N, et al. The Maccabi Glaucoma Study: treatment patterns and persistence with glaucoma therapy in a large Israeli Health Maintenance Organization. J Glaucoma. 2016;25:e386\u201391.","journal-title":"J Glaucoma"},{"key":"771_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40035-017-0090-8","volume":"6","author":"C Ma","year":"2017","unstructured":"Ma C, Liu Y, Neumann S, et al. Nicotine from cigarette smoking and diet and Parkinson\u2019s disease: a review. Transl Neurodegener. 2017;6:18.","journal-title":"Transl Neurodegener"},{"key":"771_CR10","unstructured":"Global RPh. Beta blockers: Comparative properties. 2004. \n                    http:\/\/www.globalrph.com\/beta_blockers.htm\n                    \n                  . Accessed 22 Feb 2019."},{"key":"771_CR11","first-page":"308","volume":"69","author":"M Rodr\u00edguez-Violante","year":"2017","unstructured":"Rodr\u00edguez-Violante M, Cervantes-Arriaga A, Fahn S, et al. Two-hundred years later: is Parkinson\u2019s disease a single defined entity? Rev Investig Clin. 2017;69:308\u20139.","journal-title":"Rev Investig Clin"},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s40265-014-0306-5","volume":"74","author":"S Kjeldsen","year":"2014","unstructured":"Kjeldsen S, Feldman RD, Lisheng L, et al. Updated national and international hypertension guidelines: a review of current recommendations. Drugs. 2014;74:2033\u201351.","journal-title":"Drugs."},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2337\/dc17-1406","volume":"41","author":"KK Witte","year":"2018","unstructured":"Witte KK, Drozd M, Walker AMN, et al. Mortality reduction associated with \u03b2-adrenoceptor inhibition in chronic heart failure is greater in patients with diabetes. Diabetes Care. 2018;41:136\u201342.","journal-title":"Diabetes Care."},{"issue":"6","key":"771_CR14","doi-asserted-by":"publisher","first-page":"e98961","DOI":"10.1371\/journal.pone.0098961","volume":"9","author":"YC Lee","year":"2014","unstructured":"Lee YC, Lin CH, Wu RM, et al. Antihypertensive agents and risk of Parkinson disease: a national cohort study. PLoS One. 2014;9(6):e98961.","journal-title":"PLoS One"},{"key":"771_CR15","unstructured":"ABC News. More Americans taking prescription drugs. \n                    https:\/\/abcnews.go.com\/health\/wellness\/prescription-drug-soars-us\/story?id=11547284\n                    \n                  . Accessed 26 Feb 2019."},{"key":"771_CR16","unstructured":"PRB. Population reference bureau. 2016. \n                    http:\/\/www.prb.org\/Publications\/Media-Guides\/2016\/aging-unitedstates-fact-sheet.aspx\n                    \n                  . Accessed 1 Dec 2018."},{"key":"771_CR17","unstructured":"Parkinsons News Today. Parkinson\u2019s disease statistics. 2018. \n                    https:\/\/parkinsonsnewstoday.com\/parkinsons-disease-statistics\n                    \n                  . Accessed 1 Dec 2018."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00771-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00771-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T20:27:17Z","timestamp":1583958437000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00771-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,13]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00771-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735335238.793578813","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,13]]},"assertion":[{"value":"13 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gideon Koren, Galia Norton, Kira Radinsky and Varda Shalev have no potential conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Anonymized data will be shared upon reasonable request from any qualified investigator, pending approval from Maccabi Health Services and the Assuta Research Ethics Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All procedures in this study were in accordance with the 1964 Helsinki declaration and its amendments, and the study was approved by the Assuta Ethics Committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this study is based on anonymous data, the committee waived informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}